bazedoxifene has been researched along with Bleeding in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baokun, Z; Erzhu, Y; Jianguang, X; Qiang, S; Xiaofeng, L; Xin, W; Zhiheng, C | 1 |
| Albiñana, V; Bernabéu, C; Botella, LM; Ojeda-Fernandez, L; Parra, JA; Recio, L; Zarrabeitia, R | 1 |
2 other study(ies) available for bazedoxifene and Bleeding
| Article | Year |
|---|---|
Biodegradable bilayer hydrogel membranes loaded with bazedoxifene attenuate blood-spinal cord barrier disruption via the NF-κB pathway after acute spinal cord injury.
Topics: Animals; Blood-Brain Barrier; Brain Injuries, Traumatic; Hemorrhage; Hydrogels; Inflammation; NF-kappa B; Rats; Rats, Sprague-Dawley; Spinal Cord; Spinal Cord Injuries; Tight Junction Proteins | 2023 |
Bazedoxifene, a new orphan drug for the treatment of bleeding in hereditary haemorrhagic telangiectasia.
Topics: Activin Receptors, Type II; Aged; Cells, Cultured; Endoglin; Endothelial Cells; Female; Hemorrhage; Humans; Indoles; Middle Aged; Neovascularization, Physiologic; Orphan Drug Production; Pilot Projects; RNA, Messenger; Selective Estrogen Receptor Modulators; Telangiectasia, Hereditary Hemorrhagic; Vascular Endothelial Growth Factor A; Wound Healing | 2016 |